- Home
- GMAB vs PNR Comparison
GMAB vs PNR Comparison
Compare GMAB & PNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- PNR
- Stock Information
- Founded
- GMAB 1999
- PNR 1966
- Country
- GMAB Denmark
- PNR United Kingdom
- Employees
- GMAB N/A
- PNR N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- PNR Industrial Machinery/Components
- Sector
- GMAB Health Care
- PNR Industrials
- Exchange
- GMAB Nasdaq
- PNR Nasdaq
- Market Cap
- GMAB 17.4B
- PNR 17.4B
- IPO Year
- GMAB N/A
- PNR N/A
- Fundamental
- Price
- GMAB $29.93
- PNR $109.57
- Analyst Decision
- GMAB Strong Buy
- PNR Buy
- Analyst Count
- GMAB 7
- PNR 15
- Target Price
- GMAB $41.17
- PNR $118.20
- AVG Volume (30 Days)
- GMAB 3.1M
- PNR 1.2M
- Earning Date
- GMAB 11-06-2025
- PNR 10-21-2025
- Dividend Yield
- GMAB N/A
- PNR 0.91%
- EPS Growth
- GMAB 77.72
- PNR N/A
- EPS
- GMAB 21.62
- PNR 3.93
- Revenue
- GMAB $3,646,881,232.00
- PNR $4,128,399,999.00
- Revenue This Year
- GMAB $24.25
- PNR $2.60
- Revenue Next Year
- GMAB $16.29
- PNR $3.99
- P/E Ratio
- GMAB $13.36
- PNR $27.92
- Revenue Growth
- GMAB 32.97
- PNR 0.83
- 52 Week Low
- GMAB $17.24
- PNR $74.25
- 52 Week High
- GMAB $33.65
- PNR $113.95
- Technical
- Relative Strength Index (RSI)
- GMAB 46.39
- PNR 50.04
- Support Level
- GMAB $29.57
- PNR $108.15
- Resistance Level
- GMAB $30.24
- PNR $110.86
- Average True Range (ATR)
- GMAB 0.67
- PNR 3.00
- MACD
- GMAB -0.58
- PNR -0.13
- Stochastic Oscillator
- GMAB 11.11
- PNR 63.81
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About PNR Pentair plc.
Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Its business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.1 billion in revenue in 2024.